TABLE 1. Demographic characteristics of persons who received an additional dose of COVID-19 vaccine (N = 22,191)* and completed at least one v-safe health check-in survey on days 0–7 after vaccination, by primary vaccination series and manufacturer of subsequent dose received — United States, August 12–September 19, 2021.
| Characteristic | Moderna, %† (n = 10,601) |
Pfizer-BioNTech, %† (n = 11,412) |
Janssen, %†,§ (n = 178) |
Total (N = 22,191) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dose 3 Moderna (n = 10,453; 98.6%) | Dose 3 Pfizer-BioNTech (n = 144; 1.4%) | Dose 3 Janssen (n = 4; 0.04%) | Dose 3 Pfizer-BioNTech (n = 11,209; 98.2%) | Dose 3 Moderna (n = 197; 1.7%) | Dose 3 Janssen (n = 6; 0.1%) | Dose 2 Janssen (n = 48; 27.0%) | Dose 2 Moderna (n = 64; 36.0%) | Dose 2 Pfizer-BioNTech (n = 66; 37.1%) | ||
|
Sex
| ||||||||||
| Female |
63.8 |
63.9 |
50.0 |
63.0 |
63.5 |
33.3 |
39.6 |
57.8 |
59.1 |
63.3
|
| Male |
35.1 |
34.0 |
50.0 |
36.1 |
36.0 |
66.7 |
60.4 |
42.2 |
40.9 |
35.7
|
| Unknown |
1.0 |
2.1 |
0 |
0.9 |
0.5 |
0 |
0 |
0 |
0 |
1.0
|
|
Age group, yrs
| ||||||||||
| 0–17 |
0.0 |
0.7 |
0.0 |
0.6 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.3
|
| 18–49 |
25.7 |
36.1 |
25.0 |
31.5 |
42.6 |
50.0 |
54.2 |
60.9 |
57.6 |
29.1
|
| 50–64 |
28.4 |
27.1 |
50.0 |
31.1 |
29.9 |
0.0 |
33.3 |
34.3 |
30.3 |
29.8
|
| 65–74 |
33.9 |
27.1 |
0.0 |
27.8 |
21.3 |
50.0 |
10.4 |
4.7 |
9.1 |
30.5
|
| 75–84 |
10.9 |
9.0 |
25.0 |
8.3 |
5.6 |
0.0 |
2.1 |
0.0 |
3.0 |
9.5
|
| ≥85 |
1.1 |
0.0 |
0.0 |
0.7 |
0.5 |
0.0 |
0.0 |
0.0 |
0.0 |
0.9
|
|
Ethnicity
| ||||||||||
| Hispanic/Latino |
8.0 |
15.3 |
0 |
8.2 |
5.6 |
0 |
25.0 |
6.3 |
10.6 |
8.2
|
| Non-Hispanic/Latino |
87.7 |
81.9 |
100 |
87.6 |
90.9 |
100 |
54.2 |
89.1 |
89.4 |
87.6
|
| Unknown |
4.3 |
2.8 |
0 |
4.2 |
3.6 |
0 |
20.8 |
4.7 |
0 |
4.2
|
|
Race
| ||||||||||
| AI/AN |
0.5 |
0.7 |
0 |
0.5 |
0.5 |
0 |
2.1 |
0 |
0 |
0.5
|
| Asian |
4.9 |
5.6 |
0 |
6.1 |
7.1 |
0 |
2.1 |
14.1 |
13.6 |
5.6
|
| Black |
5.6 |
3.5 |
0 |
6.2 |
1.5 |
16.7 |
6.3 |
6.3 |
9.1 |
5.9
|
| NHPI |
0.2 |
0 |
0 |
0.3 |
0.5 |
0 |
4.2 |
0 |
0 |
0.3
|
| White |
82.6 |
82.6 |
100 |
80.4 |
85.8 |
66.7 |
56.3 |
71.9 |
69.7 |
81.4
|
| Multiracial |
1.9 |
2.1 |
0 |
1.8 |
1.5 |
16.7 |
4.2 |
4.7 |
3.0 |
1.9
|
| Other |
2.1 |
4.2 |
0 |
2.1 |
0.5 |
0 |
6.3 |
1.6 |
3.0 |
2.1
|
| Unknown | 2.3 | 1.4 | 0 | 2.5 | 2.5 | 0 | 18.8 | 1.6 | 1.5 | 2.4 |
Abbreviations: AI/AN = American Indian/Alaska Native; NHPI = Native Hawaiian or other Pacific Islander.
* Percentage of registrants who completed at least one v-safe health check-in survey on days 0–7 after vaccination.
† Primary vaccination series.
§ Includes persons who received a primary Janssen single-dose and 1 additional dose of vaccine from the listed manufacturers.